A Multi-centre, Randomised, Controlled, Parallel Group, Open-label Study Evaluating the Efficacy, Safety and Tolerability of Three Doses of Colestilan (MCI-196) Compared to Standard Therapy With a Calcium-based Phosphate Binder, in Paediatric Subjects With Chronic Kidney Disease Stage 5 on Dialysis and With Hyperphosphataemia
Latest Information Update: 10 Apr 2023
Price :
$35 *
At a glance
- Drugs Colestilan (Primary) ; Phosphate binding protein modulators
- Indications Hyperphosphataemia; Kidney disorders
- Focus Registrational; Therapeutic Use
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 26 May 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov
- 16 Oct 2013 New trial record